Group 1 - Hims & Hers (HIMS) has experienced a 36% decline in its stock price, indicating it may be undervalued again as it returns to historical averages [1] - The forecasted price-to-sales (PS) ratio suggests potential for growth and value opportunities in the market [1]

Core Insights - Hims & Hers (NYSE: HIMS) is evolving from a direct-to-consumer telehealth platform into a targeted health platform with a growing base of loyal members and increasing Average Revenue Per User (ARPU) [1] Company Overview - The company is building a foundation for expansion into new health services, indicating a strategic shift towards a more comprehensive health platform [1] Financial Performance - The rise in ARPU suggests improved monetization of the customer base, reflecting the company's successful engagement strategies [1]

Core Insights - Virtual healthcare is rapidly evolving, with Hims & Hers Health, Inc. (HIMS) and American Well Corporation (AMWL) leading the charge in different segments of the market [1][2] - HIMS focuses on a direct-to-consumer model offering personalized wellness services, while AMWL targets B2B solutions for healthcare organizations [2] Company Overview - HIMS is a consumer-focused digital health platform providing services such as mental health support, skincare, sexual health, and weight-loss treatments [1] - AMWL specializes in scalable telehealth infrastructure for hospitals, insurers, and health systems, emphasizing platform development and system integration [2] Stock Performance & Valuation - Over the past three months, HIMS stock has decreased by 16%, while AMWL has increased by 0.6%. However, HIMS has seen a significant annual increase of 198.8%, compared to AMWL's decline of 14.9% [3] - HIMS has a forward price-to-sales (P/S) ratio of 3.8, above its three-year median of 2.4, while AMWL's ratio is at 0.4, below its median of 1.1 [5] Growth Metrics - HIMS reported 2.4 million subscribers in Q2 2025, marking a 30.8% year-over-year growth, with average revenue per user increasing to $74 [6][10] - AMWL's software subscriptions accounted for 57.1% of total revenue, reflecting a 47.1% year-over-year increase [12] Strategic Initiatives - HIMS is expanding internationally through acquisitions, including ZAVA, and plans to enter the Canadian market in 2026 [9] - AMWL is enhancing its business model by focusing on higher-margin subscription-based software revenues and optimizing costs, leading to a significant reduction in EBITDA losses [12][13] Earnings Projections - The Zacks Consensus Estimate for HIMS' 2025 earnings per share suggests a 122.2% improvement from 2024 [16] - For AMWL, the 2025 loss per share is projected to improve by 55.8% from 2024 [18] Price Targets - Analysts have set an average price target of $48.67 for HIMS, indicating a potential increase of 10.6% from the last close [20] - The average price target for AMWL is $9.50, suggesting a potential increase of 36.7% from the last close [21] Investment Recommendation - AMWL is positioned as a more compelling investment choice due to its focus on scalable telehealth infrastructure and lower execution risk [23] - HIMS, while showing strong profitability and user engagement, may face challenges going forward, making it less favorable for current investment [24]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Hims & Hers Health, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during a specified class period [1][2]. Group 1: Legal Investigation - The law firm is representing long-term stockholders of Hims & Hers who held shares between April 29, 2025, and June 23, 2025, and is encouraging them to discuss their legal rights [1][3]. - A class action complaint was filed on June 25, 2025, concerning the alleged misleading statements and omissions made by the company during the class period [1][2]. Group 2: Allegations Against Hims & Hers - The lawsuit claims that Hims & Hers made false statements regarding its collaboration with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy for its subscribers [2]. - Specific allegations include that Hims & Hers misrepresented the approval of its compounded semaglutide products and the partnership with Novo, which purportedly misled investors and led to a significant decline in the company's stock value [2].

Core Viewpoint - A class action securities lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud that negatively impacted investors between April 29, 2025, and June 23, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which posed risks to patient safety [2]. - It is alleged that this situation created a significant risk of termination of the Company's collaboration with Novo Nordisk [2]. - The defendants' positive statements regarding the Company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - The most shorted stocks on Wall Street, including Rocket Companies Inc, Oscar Health Inc, and Hims & Hers Health Inc, are positioned precariously, with significant short interest indicating potential for volatility and short squeezes [1][2][6]. Group 1: Company Performance - Rocket Companies has seen a remarkable increase of over 75% year-to-date, with a market capitalization nearing $40 billion and 37% of its shares sold short [3]. - Oscar Health has rebounded with a 25% increase this year, maintaining a short interest just under 30% and only 1.5 days to cover, indicating a potential for a quick squeeze [4]. - Hims & Hers has experienced a staggering 170% rise over the past year, although it has recently pulled back nearly 25%. It has a market cap of $9.7 billion and 35% of its float remains shorted, making it a high-risk short position [5]. Group 2: Market Dynamics - The current market environment is characterized by high short interest ratios and thin days to cover, suggesting that Rocket, Oscar, and Hims could transition from being heavily shorted to experiencing significant upward momentum if retail traders engage [2][6]. - The presence of retail traders looking for the next potential squeeze adds to the volatility of these stocks, making them susceptible to rapid price changes [2][6].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making materially false and misleading statements regarding its business practices and partnerships, particularly concerning the promotion of illegitimate versions of the weight-loss drug Wegovy [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Hims securities between April 29, 2025, and June 23, 2025, with a deadline of August 25, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Hims engaged in deceptive practices that jeopardized patient safety and risked the termination of its collaboration with Novo Nordisk [3][4]. Group 2: Allegations Against Hims - Specific allegations include the failure to disclose that Hims was promoting illegitimate versions of Wegovy, which posed risks to patient safety [3]. - The complaint also claims that Hims misrepresented the nature of its collaboration with Novo Nordisk, suggesting that it would ensure continued access to Wegovy for Hims subscribers [4]. Group 3: Investor Communication - Investors who suffered losses or have information related to the case are encouraged to contact the law firm Bragar Eagel & Squire for further assistance [5]. - The law firm specializes in representing individual and institutional investors in complex litigation [6].

Core Viewpoint - Class action lawsuits have been filed against Hims & Hers Health, iRobot Corporation, and Centene Corporation, alleging that these companies made materially false and misleading statements regarding their business operations and prospects, which led to investor losses [2][3][4]. Group 1: Hims & Hers Health, Inc. (NYSE: HIMS) - The class period for Hims is from April 29, 2025, to June 22, 2025, with a lead plaintiff deadline of August 25, 2025 [2]. - Allegations include deceptive promotion of illegitimate versions of Wegovy, risking patient safety, and a substantial risk of termination of collaboration with Novo Nordisk [2]. - Defendants' positive statements about the company's business were materially misleading and lacked a reasonable basis [2]. Group 2: iRobot Corporation (NASDAQ: IRBT) - The class period for iRobot is from January 29, 2024, to March 11, 2025, with a lead plaintiff deadline of September 5, 2025 [3]. - Allegations state that iRobot overstated the effectiveness of its Restructuring Plan post-Amazon Acquisition termination, raising doubts about its ability to operate profitably as a standalone company [3]. - Defendants' positive statements regarding the company's prospects were materially misleading and lacked a reasonable basis [3]. Group 3: Centene Corporation (NYSE: CNC) - The class period for Centene is from December 12, 2024, to June 30, 2025, with a lead plaintiff deadline of September 8, 2025 [4]. - Allegations include failure to disclose lower-than-anticipated enrollment and increased market morbidity based on preliminary analysis of over two-thirds of Centene's marketplace share [4]. - Defendants' positive statements about the company's business operations were materially misleading and lacked a reasonable basis [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by August 25, 2025, to serve as lead plaintiff [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, affecting investor decisions [4] - Specific claims include the failure to disclose the nature of the collaboration with Novo and the availability of weight-loss drug Wegovy for Hims subscribers [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A lead plaintiff must file a motion with the Court by August 25, 2025, to represent other class members [2] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4] - Specific claims include that Hims misrepresented the nature of its collaboration with Novo and the access to compounded semaglutide products [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading information [4]